Inogen Stock Earnings Reports

Inogen reported Q1 2026 revenue of $85.1 million, up 3.4% year-over-year and ahead of expectations, driven by strong international performance (18% growth to $37.7 million) and unit volume growth (14% YoY). U.S. sales declined 5% to $34.7 million as the market structurally shifts toward portable oxygen concentrators (POCs), pressuring direct-to-consumer and rental channels. Adjusted gross margin modestly improved to 44.7% and the company invested incrementally in R&D and commercial activity, resulting in an adjusted EBITDA loss of $1.4 million for the quarter. Management highlighted strategic diversification: expansion from a $400M POC-only market to a combined TAM of over $3.4B across oxygen therapy, sleep, airway clearance and digital health; launches include the Aurora CPAP mask (U.S.) and Rove 6 POC (Brazil); Simeox enrollment for a reimbursement trial began. Leadership additions (new CFO Jason Richardson, CMO Dominic Houlton, and a new board appointment) and a shareholder proposal to declassify the board were announced. Cash and liquidity are strong ($111.5M; no debt) and management began a share repurchase program. Guidance was reaffirmed for full-year 2026 revenue of $366M–$373M (~6% growth at midpoint) with an expectation of adjusted EBITDA improvement for the year and Q2–Q3 as seasonally stronger quarters. Management emphasized execution against a strategy of at least one new product launch per year and continued investment to drive long-term profitable growth.